SG11201708203UA - Production of oversized adeno-associated vectors - Google Patents

Production of oversized adeno-associated vectors

Info

Publication number
SG11201708203UA
SG11201708203UA SG11201708203UA SG11201708203UA SG11201708203UA SG 11201708203U A SG11201708203U A SG 11201708203UA SG 11201708203U A SG11201708203U A SG 11201708203UA SG 11201708203U A SG11201708203U A SG 11201708203UA SG 11201708203U A SG11201708203U A SG 11201708203UA
Authority
SG
Singapore
Prior art keywords
oversized
adeno
production
associated vectors
vectors
Prior art date
Application number
SG11201708203UA
Other languages
English (en)
Inventor
Sirkka Kyostio-Moore
David Souza
Karen Vincent
Original Assignee
Genzyme Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56943906&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SG11201708203U(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genzyme Corp filed Critical Genzyme Corp
Publication of SG11201708203UA publication Critical patent/SG11201708203UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10041—Use of virus, viral particle or viral elements as a vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14151—Methods of production or purification of viral material
    • C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Toxicology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
SG11201708203UA 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors SG11201708203UA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562144862P 2015-04-08 2015-04-08
US201562220067P 2015-09-17 2015-09-17
PCT/US2016/026486 WO2016164609A2 (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors

Publications (1)

Publication Number Publication Date
SG11201708203UA true SG11201708203UA (en) 2017-11-29

Family

ID=56943906

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201912912QA SG10201912912QA (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors
SG11201708203UA SG11201708203UA (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors
SG10201909381W SG10201909381WA (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201912912QA SG10201912912QA (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10201909381W SG10201909381WA (en) 2015-04-08 2016-04-07 Production of oversized adeno-associated vectors

Country Status (24)

Country Link
US (1) US10815497B2 (de)
EP (1) EP3280799A2 (de)
JP (3) JP6878299B2 (de)
KR (1) KR20170133500A (de)
CN (1) CN107864657A (de)
AU (3) AU2016245806A1 (de)
BR (1) BR112017021505A2 (de)
CA (1) CA2982123A1 (de)
CL (1) CL2017002537A1 (de)
CO (1) CO2017011344A2 (de)
CR (1) CR20170505A (de)
EA (1) EA201792236A1 (de)
EC (1) ECSP17074016A (de)
GT (1) GT201700214A (de)
HK (1) HK1246339A1 (de)
IL (3) IL283291B (de)
MX (1) MX2017012935A (de)
PE (1) PE20171800A1 (de)
PH (1) PH12017501836A1 (de)
SG (3) SG10201912912QA (de)
TN (1) TN2017000431A1 (de)
TW (1) TWI707951B (de)
UY (1) UY36611A (de)
WO (1) WO2016164609A2 (de)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS61387B2 (sr) 2013-02-15 2024-06-28 Bioverativ Therapeutics Inc Gen optimizovanog faktora viii
WO2015191508A1 (en) 2014-06-09 2015-12-17 Voyager Therapeutics, Inc. Chimeric capsids
BR112017009497A2 (pt) 2014-11-05 2018-02-06 Voyager Therapeutics, Inc. polinucleotídeos de aadc para o tratamento da doença de parkinson
RU2020108189A (ru) 2014-11-14 2020-03-11 Вояджер Терапьютикс, Инк. Композиции и способы лечения бокового амиотрофического склероза (als)
CN112410338A (zh) 2014-11-14 2021-02-26 沃雅戈治疗公司 调节性多核苷酸
US11697825B2 (en) 2014-12-12 2023-07-11 Voyager Therapeutics, Inc. Compositions and methods for the production of scAAV
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造
MA42934A (fr) 2015-09-24 2018-08-01 Biomarin Pharm Inc Vecteurs de facteur viii à virus adéno-associé, particules virales associées et formulations thérapeutiques comprenant ceux-ci
ES2926585T3 (es) 2016-02-01 2022-10-27 Bioverativ Therapeutics Inc Genes de Factor VIII optimizados
EP3448987A4 (de) 2016-04-29 2020-05-27 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
EP3448874A4 (de) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. Zusammensetzungen zur behandlung einer erkrankung
CA3024449A1 (en) 2016-05-18 2017-11-23 Voyager Therapeutics, Inc. Compositions and methods of treating huntington's disease
KR20240056729A (ko) 2016-05-18 2024-04-30 보이저 테라퓨틱스, 인크. 조절성 폴리뉴클레오티드
US11298041B2 (en) 2016-08-30 2022-04-12 The Regents Of The University Of California Methods for biomedical targeting and delivery and devices and systems for practicing the same
US11518991B2 (en) 2017-02-24 2022-12-06 Georg-August-Universitaet Goettingen Stiftung Oeffentlichen Rechts, Universitaetsmedizin Method for re-expression of different hypermethylated genes involved in fibrosis, like hypermethylated RASAL1 and use thereof in treatment of fibrosis as well as kit of parts for re-expression of hypermethylated genes including RASAL1 in a subject
MX2019013172A (es) 2017-05-05 2020-09-07 Voyager Therapeutics Inc Composiciones y metodos para tratar la enfermedad de huntington.
CA3061652A1 (en) 2017-05-05 2018-11-08 Voyager Therapeutics, Inc. Compositions and methods of treating amyotrophic lateral sclerosis (als)
WO2018213786A1 (en) * 2017-05-19 2018-11-22 Encoded Therapeutics, Inc. High activity regulatory elements
JOP20190269A1 (ar) 2017-06-15 2019-11-20 Voyager Therapeutics Inc بولي نوكليوتيدات aadc لعلاج مرض باركنسون
CA3070087A1 (en) 2017-07-17 2019-01-24 Voyager Therapeutics, Inc. Trajectory array guide system
TWI832036B (zh) 2017-08-03 2024-02-11 美商航海家醫療公司 用於aav之遞送之組合物及方法
TWI804518B (zh) 2017-10-16 2023-06-11 美商航海家醫療公司 肌萎縮性脊髓側索硬化症(als)之治療
US20200237799A1 (en) 2017-10-16 2020-07-30 Voyager Therapeutics, Inc. Treatment of amyotrophic lateral sclerosis (als)
US20210338838A1 (en) * 2018-07-20 2021-11-04 University Of Utah Research Foundation Gene therapy for macular degeneration
KR20210076051A (ko) * 2018-10-12 2021-06-23 젠자임 코포레이션 간-특이적 유전자 대체 요법에 의한 중증 pku 치료를 위한 개선된 인간 pah의 생성
WO2021042004A1 (en) * 2019-08-29 2021-03-04 Siemens Healthcare Diagnostics Inc. Reagents and methods for detecting aav shedding
WO2021067389A1 (en) 2019-09-30 2021-04-08 Bioverativ Therapeutics Inc. Lentiviral vector formulations
CN111218446B (zh) * 2019-12-25 2023-03-28 劲帆生物医药科技（武汉）有限公司 一种肝脏特异性启动子及其应用
US11254989B2 (en) * 2020-03-16 2022-02-22 The University Of North Carolina At Chapel Hill Compositions and methods for the selective detection of tumor-derived viral DNA
KR20230074703A (ko) 2020-06-24 2023-05-31 바이오버라티브 테라퓨틱스 인크. 유리 인자 viii을 상기 단백질이 발현되도록 변형된 렌티바이러스 벡터의 제제로부터 제거하는 방법
KR20230054840A (ko) 2020-07-30 2023-04-25 셰이프 테라퓨틱스 인코포레이티드 rAAV 비리온의 유도 생산을 위한 안정화된 세포주
US20220090130A1 (en) 2020-08-23 2022-03-24 Bioverativ Therapeutics Inc. MODIFIED BACULOVIRUS SYSTEM FOR IMPROVED PRODUCTION OF CLOSED-ENDED DNA (ceDNA)
MX2024002333A (es) 2021-08-23 2024-03-07 Bioverativ Therapeutics Inc Sistema de expresion de baculovirus.
EP4392445A1 (de) 2021-08-23 2024-07-03 Bioverativ Therapeutics Inc. Geschlossenerd dna-produktion mit invertierten terminalen wiederholungssequenzen
MX2024002334A (es) 2021-08-23 2024-05-23 Bioverativ Therapeutics Inc Genes optimizados del factor viii.
WO2023056331A1 (en) 2021-09-30 2023-04-06 Bioverativ Therapeutics Inc. Nucleic acids encoding factor viii polypeptides with reduced immunogenicity

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0931158A1 (de) 1996-09-06 1999-07-28 The Trustees Of The University Of Pennsylvania Indutierbare methode zur herstellung von rekombinanten adeno-assoziierten viren mittels t7 polymerase
US6989264B2 (en) 1997-09-05 2006-01-24 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
US6566118B1 (en) 1997-09-05 2003-05-20 Targeted Genetics Corporation Methods for generating high titer helper-free preparations of released recombinant AAV vectors
CA2379166C (en) 1999-08-09 2013-03-26 Targeted Genetics Corporation Enhancement of expression of a single-stranded, heterologous nucleotide sequence from recombinant viral vectors by designing the sequence such that it forms instrastrand base pairs
WO2001027303A1 (en) * 1999-10-12 2001-04-19 The University Of North Carolina At Chapel Hill Adeno-associated virus vectors encoding factor viii and methods of using the same
EP1290205B1 (de) 2000-06-01 2006-03-01 University Of North Carolina At Chapel Hill Doppelsträngige parvovirus-vektoren
US6723551B2 (en) 2001-11-09 2004-04-20 The United States Of America As Represented By The Department Of Health And Human Services Production of adeno-associated virus in insect cells
NZ618298A (en) 2001-11-13 2015-04-24 Univ Pennsylvania A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
US20040092008A1 (en) * 2002-11-12 2004-05-13 Snyder Richard O. Recombinant AAV vectors for gene therapy of hemophilia A
US7510872B2 (en) 2003-02-26 2009-03-31 Nationwide Children's Hospital Recombinant adeno-associated virus production
ATE490307T1 (de) 2003-05-21 2010-12-15 Genzyme Corp Verfahren zur herstellung von präparationen rekombinanter aav-virionen, die weitgehend frei von leeren capsiden sind
US8283151B2 (en) 2005-04-29 2012-10-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes
US7943374B2 (en) 2005-08-21 2011-05-17 Markus Hildinger Super-size adeno-associated viral vector harboring a recombinant genome larger than 5.7 kb
WO2007120542A2 (en) 2006-03-30 2007-10-25 The Board Of Trustees Of The Leland Stanford Junior University Aav capsid library and aav capsid proteins
PT3067417T (pt) 2009-06-16 2018-11-13 Genzyme Corp ¿métodos melhorados para puruficação de vetores aav recombinantes
US8663624B2 (en) 2010-10-06 2014-03-04 The Regents Of The University Of California Adeno-associated virus virions with variant capsid and methods of use thereof
JP6224459B2 (ja) 2011-02-17 2017-11-01 ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア 組織特異性を改変し、ａａｖ９媒介遺伝子導入を改善するための組成物および方法
DK2911687T3 (da) * 2012-10-26 2019-05-13 Univ Brussel Vrije Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
DK3044231T3 (da) * 2013-09-12 2020-09-07 Biomarin Pharm Inc Aav-vektorer, der omfatter en genkodningsfaktor viii primær anmodning
SG10201912977RA (en) 2014-05-02 2020-02-27 Genzyme Corp Aav vectors for retinal and cns gene therapy
LT3256594T (lt) 2015-02-10 2022-02-10 Genzyme Corporation Patobulintas virusinių dalelių tiekimas į dryžuotąjį kūną ir smegenų žievę
TWI707951B (zh) * 2015-04-08 2020-10-21 美商健臻公司 過大腺相關載體之製造

Also Published As

Publication number Publication date
JP6878299B2 (ja) 2021-05-26
JP2023116678A (ja) 2023-08-22
TN2017000431A1 (en) 2019-04-12
ECSP17074016A (es) 2018-02-28
AU2022203942A1 (en) 2022-06-23
PH12017501836A1 (en) 2018-04-23
TWI707951B (zh) 2020-10-21
IL283291A (en) 2021-07-29
TW201710498A (zh) 2017-03-16
AU2016245806A1 (en) 2017-11-30
NZ737009A (en) 2024-01-26
SG10201909381WA (en) 2019-11-28
HK1246339A1 (zh) 2018-09-07
KR20170133500A (ko) 2017-12-05
IL294965A (en) 2022-09-01
US20190048362A1 (en) 2019-02-14
SG10201912912QA (en) 2020-02-27
EA201792236A1 (ru) 2018-03-30
US10815497B2 (en) 2020-10-27
UY36611A (es) 2016-11-30
MX2017012935A (es) 2018-02-12
CR20170505A (es) 2018-01-26
IL254933A0 (en) 2017-12-31
JP2021118724A (ja) 2021-08-12
IL283291B (en) 2022-08-01
AU2024201619A1 (en) 2024-03-28
JP2018510648A (ja) 2018-04-19
CL2017002537A1 (es) 2018-05-11
CN107864657A (zh) 2018-03-30
WO2016164609A2 (en) 2016-10-13
CA2982123A1 (en) 2016-10-13
GT201700214A (es) 2018-10-24
BR112017021505A2 (pt) 2018-07-03
AU2022203942B2 (en) 2023-12-14
WO2016164609A3 (en) 2016-12-15
CO2017011344A2 (es) 2018-03-28
PE20171800A1 (es) 2017-12-28
IL254933B (en) 2021-06-30
EP3280799A2 (de) 2018-02-14

Similar Documents

Publication Publication Date Title
IL283291A (en) Production of Adno-related vectors of large size
HK1255256A1 (zh) 微生物相容性化妝品
SG10201601042PA (en) Production of ester mixtures
IL257026A (en) Solid state forms of eluxadoline
GB201508727D0 (en) Polyurethane
GB201502721D0 (en) Product
HK1252947A1 (zh) 化妝品
GB201509578D0 (en) Vectors
HK1251580B (zh) 製造膜聯蛋白v的方法
GB201521751D0 (en) Novel uses
GB201518792D0 (en) Production of proteins
HK1250719A1 (zh) 脫氧糖胺的合成
ZA201706282B (en) Solid forms of menaquinols
IL253635A0 (en) Cyclopropanebenzofuranyl pyridopyrazinedione type compounds
GB201511225D0 (en) Novel structure
GB201505800D0 (en) Motion arrangement
GB201506757D0 (en) Cosmetic
GB201516363D0 (en) Enclosed Space
ZA201707704B (en) Production of vcl4
PL3257657T3 (pl) Struktura zapobiegająca wyciekaniu
GB201601286D0 (en) Multi-eptopic construct
GB201509881D0 (en) Complementary vectors
PL3497407T3 (pl) Monitorowanie ruchu względnego dwóch elementów
GB201601249D0 (en) Production of manool
GB201521180D0 (en) Encapsulated moluscicide